YAP1 and neoplasm: Similar to the in vitro results, vemurafenib treatment was insensitive to tumor growth in RKO xenograft model (Fig. 6g), whereas the combination treatment of miR-550a-3-5p and vemurafenib sensitized the vemurafenib resistance of the RKO xenograft model through YAP inhibition (Fig. 6h, i).